Open access peer-reviewed Edited Volume

Antiviral Drugs

Farid A. Badria

Mansoura University

Prof. Badria (H-index 33) was cited by the US-based Stanford University list among the top 2% of the most-cited scientists in Medicinal and Biomolecular Chemistry(2020). He is a recipient of several awards including TWAS and WIPO. Prof. Badria is also a member of AAAS, ASP, and PAEMS.

Covering

Drug Design Antiviral Agents Pharmacology Antiviral Drugs Drug Repurposing Pharmacokinetics Herbs Food Nutraceuticals Artificial Intelligence Machine Learning (ML) Molecular Mechanism

Register your interest in contributing to this book

Collaborate with our community and contribute your knowledge.

About the book

Many viruses have periodically emerged worldwide with devastating economic, social, and health effects. Coronavirus disease 2019 (COVID-19) is the latest global pandemic virus that has lamed the whole world a heavy burden not only on the public healthcare system but also on the worldwide economy, education, and daily human life.
There is a scarce of antiviral drugs available in the market for therapy. Many pieces of research and new analytical techniques have unraveled the event and progression of a virus infection. Nowadays there's an honest understanding of the multiplication cycle of viruses, including the human immunodeficiency virus. The currently available antiviral drugs are presented arranged by their mode of action which will be understood by the multiplication cycle of the virus. The antiviral therapeutic area continues to rapidly generate meaningful new chemical entities; for instance, for HIV alone 25 drugs are approved, and within the next few years many drugs and single-tablet regimens will be approved for the treatment of hepatitis C virus infection. The increasing success within the antiviral area might be thanks to targeting drugs at "non-self" genomes and to the patient population that's tolerant of manageable side effects and adaptable to inconvenient dosing.
At present, no treatment is available, apart from symptomatic interventions, but many vaccine- and drug-based approaches are being investigated worldwide and it is too early to judge their efficacy and safety.

This book will aim to present new successful strategies; e.g artificial intelligence and better utilization of old/existing/available drugs for developing molecules with new pharmacological/therapeutic indications, high margin of safety, and reasonable economic cost.

Artificial intelligence (AI) techniques; e.g machine learning (ML) and deep learning (DL) have shown promising results in healthcare through its decision-making by analyzing the huge available perplexing data to provide rapid and reliable clinical decisions in diagnostic uncertainty or complex cases with high accuracy.

Aimed at medicinal chemists and emerging drug discovery scientists, this book will be organized based upon diverse approaches for the discovery and optimization of initial lead compounds. This book will focus on capturing tactical aspects of problem-solving in antiviral design, an approach that holds special appeal for those engaged in antiviral development, but also appeals to the broader medicinal chemistry community supported its specialization in tactical aspects of drug design.

Publishing process

Book initiated and editor appointed

Date completed: September 2nd 2021

Applications to edit the book are assessed and a suitable editor is selected, at which point the process begins.

Chapter proposals submitted and reviewed

Deadline for chapter proposals: September 30th 2021

Potential authors submit chapter proposals ready for review by the academic editor and our publishing review team.

Register for the book

Approved chapters written in full and submitted

Deadline for full chapters: November 29th 2021

Once approved by the academic editor and publishing review team, chapters are written and submitted according to pre-agreed parameters

Full chapters peer reviewed

Review results due: February 17th 2022

Full chapter manuscripts are screened for plagiarism and undergo a Main Editor Peer Review. Results are sent to authors within 30 days of submission, with suggestions for rounds of revisions.

Book compiled, published and promoted

Expected publication date: April 18th 2022

All chapters are copy-checked and typesetted before being published. IntechOpen regularly submits its books to major databases for evaluation and coverage, including the Clarivate Analytics Book Citation Index in the Web of ScienceTM Core Collection. Other discipline-specific databases are also targeted, such as Web of Science's BIOSIS Previews.

About the editor

Farid A. Badria

Mansoura University

Professor Farid Badria, Ph.D., MSc, is the recipient of several awards including The World Academy of Sciences (TWAS) Prize for Public Understanding of Science; World Intellectual Property Organization (WIPO) Gold Medal for Best Inventor; State Recognition Outstanding Award in Medicine (Egyptian Academy of Science); Outstanding Arab Scholar, Kuwait; and Khawrazmi International Award, Iran. He is also a scholar of the Arab Development Fund, Kuwait; International Cell Research Organization (ICRO)-United Nations Educational, Scientific and Cultural Organization (UNESCO) International, Chile; and UNESCO Biotechnology France. Dr. Badria has 20 patents, 250 publications, more than a dozen books, several marketed pharmaceutical products, and many plenary lectures and workshops to his credit. He continues to lead research projects on developing new therapies for liver disease, skin disorders, and cancer.

View profile

Book chapters authored 3

Books edited 6

Introducing your Author Service Manager

Mrs. Sara Gojević-Zrnić

As an Author Service Manager my responsibilities include monitoring and facilitating all publishing activities for authors and editors. From chapter submission and review, to approval and revision, copyediting and design, until final publication, I work closely with authors and editors to ensure a simple and easy publishing process. I maintain constant and effective communication with authors, editors and reviewers, which allows for a level of personal support that enables contributors to fully commit and concentrate on the chapters they are writing, editing, or reviewing. I assist authors in the preparation of their full chapter submissions and track important deadlines and ensure they are met. I help to coordinate internal processes such as linguistic review, and monitor the technical aspects of the process. As an ASM I am also involved in the acquisition of editors. Whether that be identifying an exceptional author and proposing an editorship collaboration, or contacting researchers who would like the opportunity to work with IntechOpen, I establish and help manage author and editor acquisition and contact.

Ask a question
creativecommons
alpsp
cope
stm
ithenticate
crossref
doi
oaspa

Book will be abstracted and indexed in

googlescholar
worldcat
base
az
openaire